Tekla Capital Management’s Clearside Biomedical CLSD Stock Holding History

Tekla Capital Management’s Portfolio CLSD Stock Details CLSD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-11,022	Closed	-$408K	–	192
2021 Q1	$408K	Hold	11,022	–	–	0.01%	188
2020 Q4	$453K	Hold	11,022	–	–	0.02%	192
2020 Q3	$255K	Hold	11,022	–	–	0.01%	198
2020 Q2	$311K	Hold	11,022	–	–	0.01%	215
2020 Q1	$281K	Hold	11,022	–	–	0.01%	203
2019 Q4	$479K	Hold	11,022	–	–	0.02%	196
2019 Q3	$104K	Hold	11,022	–	–	﹤0.01%	188
2019 Q2	$161K	Hold	11,022	–	–	0.01%	193
2019 Q1	$228K	Hold	11,022	–	–	0.01%	189
2018 Q4	$177K	Buy	11,022 +5,511	+100%	+$259K	0.01%	198
2018 Q3	$508K	Hold	5,511	–	–	0.02%	196
2018 Q2	$884K	Buy	+5,511	New	+$929K	0.03%	160

Other funds holding CLSD

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Carmignac Gestion Paris, France $7.71B AUM 4.02% 1-Year Est. Return

ACM

ACT Capital Management Wayne, Pennsylvania $153M AUM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACP

Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Tekla Capital Management's CLSD Position: Q2 2021 in Review

Tekla Capital Management sold out of Clearside Biomedical (CLSD) in Q2 2021, closing a stake of 11,022 shares — an estimated $408K sold.

Tekla Capital Management first reported a position in CLSD in Q2 2018 and held it in 12 quarters. The position peaked at $884K in Q2 2018. 52 funds tracked by Wall St. Rank hold CLSD as of Q2 2021.

Tekla Capital Management reported no remaining Clearside Biomedical position as of Q2 2021 after selling out during the quarter.
Tekla Capital Management sold 11,022 Clearside Biomedical shares in Q2 2021, an estimated $408K.
Tekla Capital Management first reported a position in Clearside Biomedical in Q2 2018 and held it in 12 quarters.
Tekla Capital Management's Clearside Biomedical position peaked at $884K in Q2 2018.
52 funds tracked by Wall St. Rank held Clearside Biomedical as of Q2 2021.

Based on Tekla Capital Management's 13F filing for Q2 2021, filed 13 Aug 2021.